Market Overview

UPDATE: Piper Jaffray Lowers Tornier's PT

Related TRNX
Benzinga's Top Upgrades, Downgrades For April 11, 2017
Integra LifeSciences to Acquire Total Ankle Replacement and Silastic Toe Replacement Product Portfolios from Tornier N.V.; Amount of Cash Payment Not Disclosed

According to a research report published this morning, Piper Jaffray has decreased Tornier N.V.'s (NASDAQ: TRNX) PT from $26 to $24.

In the report, Piper Jaffray said, "In-line revenues were offset by a shortfall in EPS driven by a higher tax rate and a reduction in top line and EBITDA guidance for the rest of the year, triggered by changes in U.S. distribution. The market has been fairly unforgiving of any shortfall or change in outlook, and quickly priced in the guidance change, as well as additional discounts for general concerns regarding the company's end markets and management's ability to deliver on its long-term commitments to margin expansion. Given that the majority of the reduction in outlook for revenues and adjusted EBITDA margins was driven by transitory changes in distributors in the U.S., we see growth and margins improving in 2H12 and beyond, aided by new products, new geographies and improving U.S. utilization trends."

Piper Jaffray maintains its Overweight rating on Tornier, which closed Friday at $20.98.

Latest Ratings for TRNX

May 2015Northland SecuritiesInitiates Coverage onMarket Perform
Nov 2014BarclaysMaintainsOverweight
Nov 2014PiperJaffrayDowngradesOverweightNeutral

View More Analyst Ratings for TRNX
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (TRNX)

View Comments and Join the Discussion!

Partner Center